H.C. Wainwright analyst Douglas Tsao downgraded Amryt Pharma to Neutral from Buy with a price target of $14.50, down from $18, after the company announced last week that it has agreed to be acquired by Chiesi. His new price target of $14.50 is based on the acquisition price agreed with Chiesi Farmaceutici.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on AMYT: